期刊
EXPERT OPINION ON DRUG DISCOVERY
卷 6, 期 11, 页码 1155-1170出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17460441.2011.625652
关键词
assay; cardiovascular; drugs; platform; screening; systems; technology
资金
- British Heart Foundation [FS2000020, FS/04/088, BS/04/002, FS/06/082/21723, FS/09/028/27602]
- Royal Society
- Wellcome Trust [094210/Z/10/Z]
- Cardiff University
- Wellcome Trust [094210/Z/10/Z] Funding Source: Wellcome Trust
- British Heart Foundation [FS/09/028/27602] Funding Source: researchfish
Introduction: The pharmaceutical industry urgently needs new ways of profiling the safety and efficacy of new cardiovascular (CV) drugs and more effectively transitioning these compounds through the stages of CV drug screening. This article reviews new technologies and methodological innovations and assesses whether these frameworks offer improved solutions to the problems facing the contemporary CV drug development. Areas covered: The article comprises literature derived from a systematic search (from 2000 onwards) using the US patent office and ESP@CENET search engines as well as through multiple Boolean terms. The article focuses on patents relating to technologies and resources and categorises the patents according to their niche in the CV drug screening landscape. Expert opinion: The CV drug pipeline is stalling due to the inability of many contemporary drug screening frameworks to discriminate between safe, efficacious therapy and hazardous off-target effect. Given the current limitations of drug screening frameworks, there is little scope for expanding the CV drug portfolio with newer, safer drugs with improved mechanisms of action. New screening modalities are urgently needed. Searches reveal that there are few examples of truly new technologies and systems in the patent literature. This apparent failure to revamp facets of the CV drug screening process can only perpetuate the inability of current platforms to improve the CV drug pipeline. Consequently, with few exceptions, there is stagnation in preclinical assay design that limits the pharmaceutical industry's ability to search for new drugs in new and more effective ways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据